Sanofi, Regeneron announce positive Phase 2a study results of asthma drug
The study of the IL-4R alpha inhibitor demonstrated 87% reduction in risk of asthma exacerbations in moderate-to-severe asthma patients with elevated eosinophils. Trial lead investigator and the University
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.